Tobacco Use and HIV in Low and Middle Income Countries
PAR-18-023 (R01), PAR-18-022 (R21)

The purpose of these FOAs is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low- and middle-income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV-positive populations, including those with comorbidities such as tuberculosis, in low-resource settings in LMICs.

Expiration: January 8, 2020
NCI Contact: Mark Parascandola, 240-276-6871, Mark.Parascandola@nih.gov

U.S. Tobacco Control Policies to Reduce Health Disparities
PAR-18-675 (R01), PAR-18-674 (R21)

These FOAs are intended to stimulate scientific inquiry focused on innovative tobacco control policies, with the long-term goal of reducing disparities in health outcomes focused on excess disease burden of tobacco use. The policy approaches funded by these FOAs may be existing ones studied to understand how to improve their effectiveness to reduce health disparities, or they may be new policy approaches to reduce health disparities in tobacco use. This initiative will support observational or intervention research focused on reducing health disparities in tobacco use in the United States.

Release Date: February 21, 2018
Expiration: June 16, 2020
NCI Contact: Bob Vollinger, 240-276-6919, Bob.Vollinger@nih.gov and Annette Kaufman, 240-276-6706, Annette.Kaufman@nih.gov

Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions
PAR-18-251 (R01), PAR-18-250 (R21)

The purpose of these FOAs is to provide support for highly innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Specifically, these FOAs are intended to stimulate research efforts aimed at the development of smoking cessation interventions that: 1) are targeted to socioeconomically disadvantaged populations, and 2) could be made scalable for broad population impact. Applicants may propose projects that develop and test novel cessation interventions with the potential to be scaled up, and projects that focus on enhancing the effectiveness, quality, accessibility, utilization and cost-effectiveness of currently scaled smoking cessation interventions.

Expiration: June 14, 2019
NCI Contact: Yvonne Hunt Prutzman, 240-276-6975, Yvonne.Hunt@nih.gov

Dissemination and Implementation Research in Health
PAR-18-007 (R01), PAR-18-017 (R21), PAR-16-237 (R03)

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Expiration: May 8, 2019
NCI Contact: David Chambers, 240-276-5090, dchamber@mail.nih.gov

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-18-484 (R01)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

This FOA does not accept applications proposing clinical trial(s).
Expiration: January 8, 2021
NCI Contact: Michele Bloch, 240-276-6878, blochm@mail.nih.gov

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
PAR-18-559 (R01)

Through this FOA, the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.
Expiration: January 8, 2021
NCI Contact: Susan Czajkowski, 240-276-5871, czajkows@mail.nih.gov

https://cancercontrol.cancer.gov/brp/funding/funding-opportunities.html#tcrb
Notice to Study the Population Impact of the Court-Ordered, Tobacco-Related Corrective Statements
PAR-18-064 (R21)
The purpose of this notice is to inform potential applicants that the National Cancer Institute (NCI) is participating in PAR-18-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)". The PAR has been modified to include the following language in the Full Text of the Announcement: In addition to research areas already listed in the Funding Opportunity Description, the National Cancer Institute (NCI) is interested in applications that address an extraordinary opportunity in this area by: Utilizing natural experiment, observational, or ecological designs to study the population impact of the court-ordered, tobacco-related corrective statements implemented as part of the Department of Justice’s racketeering case, “United States v. Philip Morris USA, Inc,” which are currently being disseminated on television and in newspapers and soon will be disseminated on tobacco company Web sites, cigarette pack inserts, and possibly at point-of-sale.
Expiration: November 9, 2018
NCI Contact: Kelly Blake, 240-281-5934, kelly.blake@nih.gov

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)
PAR-18-612 (R01)
The intent of this FOA is to encourage researchers to generate data to address gaps in our understanding of population-based, clinical and applied prevention of disease related to Electronic Nicotine Delivery Systems (ENDS). Particularly, the goal of these studies are to better understand the impact of ENDS use on the prevention of disease or the risk of disease, relationships of use with other tobacco products and how that affects addiction to nicotine, alcohol and other drugs, as well as the effects of second and third hand exposure to the aerosol.
Expiration: June 28, 2020
NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes
PA-17-135 (R01), PA-17-132 (R21), PA-17-134 (R03)
The purpose of these FOAs is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol, marijuana, and other drugs. These FOAs are intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health.
Expiration: May 8, 2020
NCI Contact: Carolyn Reyes-Guzman, 240-276-7244, Carolyn.Reyes-Guzman@nih.gov

Accelerating the Pace of Drug Abuse Research Using Existing Data
PAR-18-062 (R01)
The purpose of this FOA is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors, and their consequences, including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Expiration: May 8, 2019
NCI Contact: Erik Augustson, 240-276-6774, Erik.Augustson@nih.gov

Tobacco Regulatory Science
RFA-OD-18-002 (R01), RFA-OD-18-003 (R21)
The purpose of these FOAs is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of FDA CTP. The awards under these FOAs will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from these FOAs are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Expiration: February 14, 2019
NCI Contact: Rachel Grana Mayne, 240-276-5899, Rachel.Mayne@nih.gov

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services
PAR-18-222 (R01)
The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services. This FOA is part of the trans-NIH initiative known as Collaborative Research on Addiction at NIH.
Expiration: November 14, 2020
NCI Contact: Glen Morgan, 240-276-6787, Glen.Morgan@nih.gov

*Not a comprehensive list of all tobacco-related FOAs; please consult the NIH Guide for all available funding opportunities.